logo
Use App

Products

Logo

Gold Vault

Buy gold & silver at live MCX Prices, store securely at vault & get doorstep delivery.

Logo

DEXT T3 Trading Terminal

Terminal Built for Power Traders - Get Speed, Flexibility, and Complete control.

Logo

Dhan App

Stock Market App built for Super Traders & Long Term Investors.

Logo

Dhan Web

Web Trading Platform for those who love to trade from the big screen.

Logo

Options Trader App

Option Trading App built especially for India's F&O Traders.

Logo

Options Trader Web

Option Trading Platform to build, analyze, & execute F&O trades.

Logo

Trade from tv.dhan.co

Trade with TradingView Chart features for FREE on tv.dhan.co.

Logo

Connect to TradingView

Connect Dhan to TradingView - Place orders from tradingview.com

Logo

DhanHQ Trading APIs

Trade with Algo, Connect Apps, Build Services using APIs for FREE.

Logo

smallcases on Dhan

Build wealth with smallcase investment for FREE on Dhan.

Logo

Margin Trading Facility

Get 4X Leverage on 1700+ stocks. Trade Now, Pay Later.

Logo

ScanX Stock Screener

50+ Readymade Screeners, Live Market Insights & Instant Trade Execution.

Logo

Rent Stocks via SLBM

Earn up to 35% p.a. over & above your portfolio holdings!

PricingOpen Demat Account at ₹0 AMCBecome a PartnerCustomer ServiceDhan SupportDhan Blog
fuzz
Logo
MadeForTrade CommunityIndicator by Dhan
Home
InvestmentsIPOSymbiotec Pharmalab IPO

Symbiotec Pharmalab IPO

Mainboard

Open Date

24 Aug 2026

Close Date

27 Aug 2026

Min Investment

₹ 14,820

Lot Size

15

Issue Size

₹ 1757.30 Cr

Price Range

₹ 938 - ₹ 988

Subscribed

1.32 x
Apply Now
status

IPO Open Now.

IPO Timeline
check
IPO Offer Start
24 Aug 2026
check
IPO Offer Ends
27 Aug 2026
check
Allotment Finalisation
28 Aug 2026
check
Refund Initialisation
31 Aug 2026
check
Non-Institutional Buyers (sHNI)
31 Aug 2026
check
Listing of Shares
1 Sep 2026
IPO Subscription Details as on 25 Aug 2026, 12:34 PM
Qualified Instituational Buyers (QiB)
0.54 x
Retail
1.54 x
Employees
2.24 x
Total
1.32 x
Non-Institutional Buyer (bHNI)
1.41 x
Non-Institutional Buyer (sHNI)
2.69 x
Note: This information is provided for general guidance only. Dates may be subject to change.
border
About the Company
Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology and complex injectables. The company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) in volume terms, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs. The company operates as a contract development and manufacturing organisation (CDMO) for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms.
rocket

Founded In

2002

rocket

Director

Rohit Mantri

img

DRHP

img

Financials of Symbiotec Pharmalab IPO

Income Statement
Balance Sheet
Cash Flows
Total Income
Total Expenses
Total Profit
Key Performance IndicatorsMar 2024Mar 2025Mar 2026
Operating Revenue716.25751.55869.15
Other Income7.094.423.11
Total Income
723.33755.98872.26
Total Expenses
590.99608.85709.90
Profit Before Tax130.98146.97153.36
Total Profit
100.0696.79109.90

All figures are in crores (₹)

border

Utilisation of Proceeds

All figures are in crores (₹)

PurposeAmount
The company proposes to utilize the net proceeds towards prepayment and/or repayment, in full or in part, of certain outstanding borrowings to reduce overall indebtedness, debt servicing costs, and maintain favorable debt-equity ratio.113
The company proposes to utilize the balance net proceeds for general corporate purposes including meeting ongoing contingencies, business requirements, funding growth opportunities, and strategic initiatives as approved by the Board.-
border
  • Global leadership in corticosteroid and steroidal-hormone APIs: The company holds a global leadership position with 38.2% market share in corticosteroid and 23.8% in steroidal-hormone APIs in Fiscal 2026, being the only company globally with presence across top 10 APIs in this category.
  • Long-standing relationships with domestic and global customer base: The company serves over 200 customers across 40+ countries with average relationship tenure of more than 10 years with top customers, demonstrating strong customer stickiness and retention capabilities.
  • Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record: The company operates with 584.67 MT chemical synthesis capacity, 700 KL fermentation capacity, and 20 million vials complex injectables capacity, having completed 108+ inspections without critical observations from global regulators.
  • Continuous investment in R&D, with leading technological capabilities among Indian peers: The company invested 3.42% of revenue in R&D in Fiscal 2026 with 156 scientists across three platforms, enabling manufacturing of APIs with up to 400 synthesis steps validated under cGMP.
  • Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings: The company successfully expanded into classical fermentation APIs, CDMO services with take-or-pay contracts, and complex injectables commanding 20-50% price premium over conventional injectables.
  • Robust financials with strong gross margins, high capital efficiency and cash conversion: The company achieved revenue CAGR of 10.16% (Fiscal 2024-2026), gross margins of 63.70% in Fiscal 2026, and maintained CARE A+ credit rating across three consecutive fiscals.
  • Seasoned leadership team supported by strong pool of experienced management and marquee investors: The company is led by experienced management with 30+ years pharmaceutical experience, backed by marquee investors including Rosewood Investments, Motilal Oswal Alternates, and historically Actis and Franklin Templeton.

Open IPOs for Subscription

No Open IPOs

Stay tuned, there will be more IPOs listing soon!


fuzz

Listed IPOs

No Listed IPOs

Stay tuned, there will be more IPOs listing soon!


Invest & Trade with a Trading
Platform That's #MadeForTrade

Open your Dhan Account in minutes!
Start Now
border
logo

Join our Community

community logo

Follow us on

twitter
telegram
Linkedin
youtube
instagram
facebook

built with love
for Indians who love to invest & trade

raise

We are part of Raise Financial Services

raise
raise

Explore  |  Sitemap


*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

We are doing so by giving you access to not just one but 6 products within the Dhan ecosystem:


This means that with Dhan, you'll be able to start:


Lakhs of users already trust Dhan for their online stock trading and investing needs. Dhan is growing rapidly because of the love we receive from SuperTraders and Long-Term Investors who acknowledge that the platform is innovating for them, building super useful features that help them do everything from investing in stock market to trading F&O like a pro on the Tradingview charts and much more.

While we are growing, we will always remember why we started building in the first place - you. Our user-first approach will always be at the heart of our philosophy. Come join us on this incredible journey!

Try it out, you can close your account at anytime using this link.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.

Details of client bank account

For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution